BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a strong sell rating to a sell rating in a research report released on Saturday.

Several other research analysts have also recently commented on NTRA. Zacks Investment Research raised Natera from a sell rating to a hold rating in a research report on Friday, September 22nd. Morgan Stanley reissued an overweight rating and set a $16.00 price target (up from $13.00) on shares of Natera in a research report on Friday, October 6th. Robert W. Baird reissued a buy rating on shares of Natera in a research report on Tuesday, October 24th. Canaccord Genuity reissued a buy rating and set a $15.00 price target on shares of Natera in a research report on Tuesday, November 14th. Finally, Cowen reissued a buy rating and set a $12.00 price target on shares of Natera in a research report on Thursday, December 21st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $14.50.

Shares of Natera (NASDAQ:NTRA) traded up $0.81 during midday trading on Friday, reaching $11.11. The company had a trading volume of 216,557 shares, compared to its average volume of 86,632. Natera has a 1 year low of $7.35 and a 1 year high of $14.76. The company has a quick ratio of 1.75, a current ratio of 1.85 and a debt-to-equity ratio of 2.43. The firm has a market capitalization of $597.37, a PE ratio of -4.53 and a beta of 2.07.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The company had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. During the same period last year, the company posted ($0.50) earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. sell-side analysts forecast that Natera will post -2.15 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Schwab Charles Investment Management Inc. lifted its position in shares of Natera by 20.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 109,594 shares of the medical research company’s stock valued at $1,191,000 after buying an additional 18,970 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Natera by 23.0% in the second quarter. Rhumbline Advisers now owns 34,533 shares of the medical research company’s stock valued at $375,000 after buying an additional 6,465 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Natera by 1.5% in the second quarter. Bank of New York Mellon Corp now owns 634,743 shares of the medical research company’s stock valued at $6,893,000 after buying an additional 9,223 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Natera by 1.3% in the second quarter. Principal Financial Group Inc. now owns 112,687 shares of the medical research company’s stock valued at $1,224,000 after buying an additional 1,409 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Natera in the second quarter valued at approximately $151,000. 66.06% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/21/bidaskclub-upgrades-natera-ntra-to-sell.html.

About Natera

Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.